Anti-IGF-IR antibodies and uses thereof

Details Anti-IGF-IR antibodies and uses thereof Anti-IGF-IR antibodies and uses thereof

2007-07-10

2007-07-10

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S134100, C424S135100, C424S141100, C424S143100, C425S007000, C425S810000, C530S387100, C530S387300, C530S381000, C530S391300

Reexamination Certificate

active

10735916

ABSTRACT:
The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.

REFERENCES:
patent: 5608039 (1997-03-01), Pastan et al.
patent: 5891996 (1999-04-01), Mateo de Acosta del Rio et al.
patent: 5935821 (1999-08-01), Chatterjee et al.
patent: 6068841 (2000-05-01), Seino et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6235883 (2001-05-01), Jakobovits et al.
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 3018541 (2000-01-01), None
patent: WO 96/40210 (1996-12-01), None
patent: WO 01/88138 (2001-11-01), None
patent: WO 02/053596 (2002-07-01), None
Janway et al, p. 3:1-3:3, in Immunobiology, 1994.
Traxler et al, J Pharm Belg 52(2): 88-96, 1997.
Ciardiello et al, Clinical Cancer Research 5: 909-916, Apr. 1999.
Baselga et al, Semin Oncol 26(4 suppl 12): 78-83, Aug. 1999, abstract only.
Rodeck et al, J Cell Biochem 35(4): 315-20, Dec. 1987.
Bartucci et al., “Differential Insulin-like Growth Factor I Receptor Signaling and Function in Estrogen Receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 Breast Cancer Cells”, Cancer Research, Sep. 15, 2001, pp. 65747-6754, vol. 61.
Putz et al., “Epidermal Growth Factor (EGF) Receptor Blockade Inhibits the Action of EGF, Insulin-like Growth Factor I, and a Protein Kinase A Activator on the Mitogen-activated Protein Kinase Pathway in Prostate Cancer Cell Lines”, Cancer Research, Jan. 1, 1999, pp. 227-233, vol. 59.
Coppola et al., “A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activites of the Epidermal Growth Factor Receptor”, Molecular and Cellular Biology, Jul. 1994, pp. 4588-4595, vol. 14, No. 7, American Society for Microbiology.
Cheatham et al., “Insulin Action and the Insulin Signaling Network”, Endocrine Reviews, 1995, pp. 117-142, vol. 16, No. 2, The Endocrine Society.
Singer et al., “Optimal Humanization of 1B4, and Anti-CD18 Murine Monoclonal Antibody, is Achieved by Correct Choice of Human V-Region Framework Sequences”, The Journal of Immunology, Apr. 1, 1993, pp. 2844-2857, vol. 150, No. 7, The American Association of Immunologists.
Pastorino et al., “Doxorubicin-loaded Fab' Fragments of Anti-disialoganglioside Immunoliposomes Selectively Inhibit the Growth and Dissemination of Human Neuroblastoma in Nude Mice” Cancer Research, Jan. 1, 2003, pp. 86-92, vol. 63.
Glennie et al., “Preparation and Performance of Bispecific F(ab'γ)2Antibody Containing Thioether-Linked Fab'γ Fragments”, The Journal of Immunology, Oct. 1, 1987, pp. 2367-2374, vol. 139, No. 7, The American Association of Immunologists.
Bebbington et al., “High-Level Expression of a Recombinant Antibody from Myeloma Cells using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker”, Bio/Technology, Feb. 1992, pp. 169-175, vol. 10.
Amit et al., “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution”, Science, Aug. 15, 1986, pp. 747-753, vol. 233.
Caton et al., “Identical D Region Sequences Expressed by Murine Monoclonal Antibodies Specific for a Human Tumor-Associated Antigen”, The Journal of Immunology, Mar. 1, 1990, pp. 1965-1968, vol. 144, No. 5, The American Association of Immunologists.
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, J. Mol. Biol., 1987, pp. 901-917, vol. 196, Academic Press Limited.
Chothia et al., “Conformations of immunoglobulin hypervarible regions”, Nature, Dec. 1989, pp. 877-883, vol. 342, 21/28.
Sharon, “Structural Characterization of Idiotapes by using Antibody Variants Generated by Site-Directed Mutagenesis”, The Journal of Immunology, Jun. 15, 1990, pp. 4863-4869, vol. 144, No. 12, The American Association of Immunologists.
Connolly, et al., “Regulation of DUI45 Human Prostate Cancer Cell Proliferation by Insulin-Like Growth Factors and its Interaction with the Epidermal Growth Factor Autocrine Loop”, The Prostate, 1994, pp. 167-175, vol. 24, Wiley-Liss, Inc.
Kabat, et al., “Identical V Region Amino Acid Sequences and Segments of Sequences in Antibodies of Different Specificities”, The Journal of Immunology, Sep. 1, 1991, pp. 1709-1719, vol. 147, No. 5, The American Association of Immunologists.
Laguzza et al., “New Antitumor Monoclonal Antibody-Vinca Conjugates LY203725 and Related Compounds: Design, Preparation, and Representative in Vivo Activity”, J. Med. Chem., 1989, pp. 548-555, vol. 32, American Chemical Society.
Fisher et al., “Endometrial Cancer in Tamoxifen—Treated Breast Cancer Patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14”, Journal of the National Cancer Institute, Apr. 6, 1994, pp. 527-537, vol. 86, No. 7.
Guvakova et al., “Tamoxifen Interferes witht he Insulin-like Growth Factor I Receptor (IGF-IR) Signaling Pathway in Breast Cancer Cells”, Cancer Research, Jul. 1, 1997, pp. 2606-2610, vol. 57.
Forbes, “The Control of Breast Cancer: The Role of Tamoxifen”, Seminars in Oncology, Feb. 1997, pp. SI-5-SI-19, vol. 24, No. 1, Suppl 1.
Kullberg et al., “Tumor-Cell Targeted Epidermal Growth Factor Liposomes Loaded with Boronated Acridine: Uptake and Processing”, Pharmaceutical Research, Feb. 2003, pp. 229-236, vol. 20, No. 2, Plenum Publishing Corporation.
Suresh et al., “[17] Bispecific Monoclonal Antibodies from Hybrid Hybridomas”, Methods in Enzymology, 1986, pp. 210-228, vol. 121, Academic Press, Inc.
Monfar et al., “Activation of pp70/85 S6 Kinases in Interluken-2-Responsive Lymphoid Cells is Mediated by Phosphatidylinositol 3-Kinase and Inhibited by Cyclic AMP”, Molecular and Cellular Biology, Jan. 1995, pp. 326-337, vol. 15, No. 1, American Society for Microbiology.
Yamada et al., “Role of the Transmembrane Domain and Flanking Amino Acids in Internalization and Down-Regulation of the Insulin Receptor”, The Journal of Biological Chemistry, Feb. 17, 1995, pp. 3115-3122, vol. 270, No. 7, The American Society for Biochemistry and Molecular Biology, Inc.
Ciardiello, “Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents”, Drugs, 2000, pp. 25-32, 60 Suppl. 1, Adis International Limited.
Petersen et al., “The Human Immune Response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies”, Cancer Research, 1991, pp. 2286-2290, vol. 51, Issue 9, American Association for Cancer Research (Abstract only).
Laviola et al., “The Adapter Protein Grb10 Associates Preferentially with the Insulin Receptor as Compared with the IGF-I Receptor in Mouse Fibroblasts”, J. Clin. Invest., Mar. 1997, pp. 830-837, vol. 99, No. 5, The American Society for Clinical Investigation, Inc.
Masquelier et al., “Amino Acid and Depeptide Derivatives of Daunorubicin. 1. Synthesis, Physiocochemical Properties, and L

Affiliated with

Also associated with

Rating

Anti-IGF-IR antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-IGF-IR antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IGF-IR antibodies and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3754185